KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Convertible Debt: 2022-2024

Historic Convertible Debt for Alnylam Pharmaceuticals (ALNY) over the last 3 years, with Dec 2024 value amounting to $1.0 billion.

  • Alnylam Pharmaceuticals' Convertible Debt rose 1.62% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1.62%. This contributed to the annual value of $1.0 billion for FY2024, which is 0.38% up from last year.
  • Alnylam Pharmaceuticals' Convertible Debt amounted to $1.0 billion in FY2024, which was up 0.38% from $1.0 billion recorded in FY2023.
  • Alnylam Pharmaceuticals' Convertible Debt's 5-year high stood at $1.0 billion during FY2024, with a 5-year trough of $1.0 billion in FY2022.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Convertible Debt value was $1.0 billion (recorded in 2023), while the average stood at $1.0 billion.
  • Data for Alnylam Pharmaceuticals' Convertible Debt shows a peak YoY grew of 0.38% (in 2023) over the last 5 years.
  • Over the past 3 years, Alnylam Pharmaceuticals' Convertible Debt (Yearly) stood at $1.0 billion in 2022, then grew by 0.38% to $1.0 billion in 2023, then climbed by 0.38% to $1.0 billion in 2024.